Market Closed -
Hong Kong S.E.
04:08:06 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
24.45
HKD
|
+2.52%
|
|
+4.71%
|
+16.99%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16,708
|
8,413
|
4,747
|
6,088
|
7,237
|
-
|
-
|
Enterprise Value (EV)
1 |
12,248
|
5,924
|
4,367
|
6,088
|
6,550
|
6,480
|
7,261
|
P/E ratio
|
-0.86
x
|
-8.24
x
|
-18.5
x
|
-
|
-11.4
x
|
-47.2
x
|
453
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
155,805
x
|
371
x
|
48.3
x
|
10.7
x
|
4.76
x
|
2.99
x
|
EV / Revenue
|
-
|
109,710
x
|
341
x
|
48.3
x
|
9.73
x
|
4.26
x
|
3
x
|
EV / EBITDA
|
-18.3
x
|
-5.95
x
|
-20.4
x
|
-
|
-14.6
x
|
115
x
|
19.8
x
|
EV / FCF
|
-12.8
x
|
-7.32
x
|
-
|
-
|
-5.4
x
|
-20.4
x
|
-31.7
x
|
FCF Yield
|
-7.81%
|
-13.7%
|
-
|
-
|
-18.5%
|
-4.89%
|
-3.15%
|
Price to Book
|
0.71
x
|
1.41
x
|
0.81
x
|
-
|
1.84
x
|
1.88
x
|
-
|
Nbr of stocks (in thousands)
|
293,222
|
296,715
|
309,246
|
320,493
|
319,835
|
-
|
-
|
Reference price
2 |
56.98
|
28.36
|
15.35
|
19.00
|
22.63
|
22.63
|
22.63
|
Announcement Date
|
3/22/21
|
3/28/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.054
|
12.8
|
125.9
|
673.3
|
1,522
|
2,418
|
EBITDA
1 |
-
|
-668.1
|
-995.2
|
-214
|
-
|
-450.2
|
56.3
|
366.8
|
EBIT
1 |
-
|
-688.5
|
-1,054
|
-256.8
|
-932.7
|
-649.4
|
-155.5
|
-96.4
|
Operating Margin
|
-
|
-
|
-1,952,274.07%
|
-2,006.25%
|
-740.67%
|
-96.44%
|
-10.22%
|
-3.99%
|
Earnings before Tax (EBT)
1 |
-
|
-5,658
|
-1,009
|
-247.3
|
-844.5
|
-623.5
|
-138.2
|
18.82
|
Net income
1 |
-214.5
|
-5,658
|
-1,009
|
-247.3
|
-844.5
|
-623.5
|
-150.6
|
16
|
Net margin
|
-
|
-
|
-1,867,962.96%
|
-1,932.03%
|
-670.57%
|
-92.6%
|
-9.89%
|
0.66%
|
EPS
2 |
-41.04
|
-66.29
|
-3.440
|
-0.8300
|
-
|
-1.986
|
-0.4791
|
0.0500
|
Free Cash Flow
1 |
-
|
-956.4
|
-808.8
|
-
|
-
|
-1,214
|
-317
|
-229
|
FCF margin
|
-
|
-
|
-1,497,844.44%
|
-
|
-
|
-180.31%
|
-20.83%
|
-9.47%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/20/20
|
3/22/21
|
3/28/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
0.054
|
1.044
|
11.76
|
8.9
|
252.7
|
459.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-406.3
|
-653.9
|
-639.6
|
382.8
|
-
|
-340.1
|
-295.1
|
Operating Margin
|
-
|
-
|
-1,210,977.78%
|
-61,269.16%
|
3,256.63%
|
-
|
-134.57%
|
-64.19%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
420.8
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
420.7
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
3,578.96%
|
-
|
-
|
-
|
EPS
2 |
-
|
-1.310
|
-2.130
|
-2.260
|
1.430
|
-
|
-1.010
|
-0.8300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/21
|
8/30/21
|
3/28/22
|
8/24/22
|
3/30/23
|
8/24/23
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.4
|
Net Cash position
1 |
-
|
4,460
|
2,489
|
380
|
-
|
687
|
757
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0665
x
|
Free Cash Flow
1 |
-
|
-956
|
-809
|
-
|
-
|
-1,214
|
-317
|
-229
|
ROE (net income / shareholders' equity)
|
-
|
-189%
|
-15.8%
|
-4.28%
|
-
|
-14%
|
-5.94%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-118%
|
-14.3%
|
-3.73%
|
-
|
-16.5%
|
-6.7%
|
-
|
Assets
1 |
-
|
4,807
|
7,061
|
6,631
|
-
|
3,779
|
2,247
|
-
|
Book Value Per Share
2 |
-
|
80.20
|
20.10
|
19.00
|
-
|
12.30
|
12.00
|
-
|
Cash Flow per Share
2 |
-
|
-5.530
|
-2.490
|
-3.880
|
-
|
-2.660
|
-0.6100
|
-
|
Capex
1 |
-
|
485
|
79
|
356
|
-
|
450
|
200
|
200
|
Capex / Sales
|
-
|
-
|
146,277.78%
|
2,780.59%
|
-
|
66.84%
|
13.14%
|
8.27%
|
Announcement Date
|
9/20/20
|
3/22/21
|
3/28/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
22.63
CNY Average target price
25.92
CNY Spread / Average Target +14.55% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.99% | 1B | | -4.24% | 86.85B | | +2.76% | 40.16B | | -16.98% | 31.28B | | +57.86% | 25.27B | | -16.24% | 15.33B | | -9.12% | 11.96B | | -42.56% | 11.61B | | -17.10% | 11.69B | | +6.89% | 8.83B |
Biopharmaceuticals
|